Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.07 (-5.06%)
Close on Nov 13, 2026Market cap $1.34MP/E –Yield –
Transcode Therapeutics cash
Cash and short-term investments held at the end of each period.
Transcode Therapeutics's cash was $8.38M at Jun 30, 2026. For fiscal 2025 it was $17.81M, up 206.5% from the year before. The highest annual figure on record is $20.83M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.81M | +206.5% |
| FY2024 | Dec 31, 2024 | $5.81M | +110.0% |
| FY2023 | Dec 31, 2023 | $2.77M | -44.3% |
| FY2022 | Dec 31, 2022 | $4.97M | -76.1% |
| FY2021 | Dec 31, 2021 | $20.83M | +2415.2% |
| FY2020 | Dec 31, 2020 | $828.02K | +305.0% |
| FY2019 | Dec 31, 2019 | $204.47K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.38M | +13.7% |
| Q1 FY2026 | Mar 31, 2026 | $12.84M | +10.9% |
| Q4 FY2025 | Dec 31, 2025 | $17.81M | +206.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.84M | +51.2% |
| Q2 FY2025 | Jun 30, 2025 | $7.37M | +119.8% |
| Q1 FY2025 | Mar 31, 2025 | $11.57M | +135.4% |
| Q4 FY2024 | Dec 31, 2024 | $5.81M | +110.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.88M | -74.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.35M | -6.1% |
| Q1 FY2024 | Mar 31, 2024 | $4.91M | +202.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.77M | -44.3% |
| Q3 FY2023 | Sep 30, 2023 | $7.45M | -15.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.57M | -73.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.62M | -90.4% |
| Q4 FY2022 | Dec 31, 2022 | $4.97M | -76.1% |
| Q3 FY2022 | Sep 30, 2022 | $8.79M | -60.9% |
| Q2 FY2022 | Jun 30, 2022 | $13.44M | +16789.4% |
| Q1 FY2022 | Mar 31, 2022 | $16.85M | +16929.4% |
| Q4 FY2021 | Dec 31, 2021 | $20.83M | +2415.2% |
| Q3 FY2021 | Sep 30, 2021 | $22.50M | +1953.0% |
| Q2 FY2021 | Jun 30, 2021 | $79.57K | -93.8% |
| Q1 FY2021 | Mar 31, 2021 | $98.96K | -51.6% |
| Q4 FY2020 | Dec 31, 2020 | $828.02K | – |
| Q3 FY2020 | Sep 30, 2020 | $1.10M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.29M | – |
| Q4 FY2019 | Dec 31, 2019 | $204.47K | – |
See a number that looks wrong?